Timelo Investment Management Inc. raised its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 2,597.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 809,095 shares of the company's stock after acquiring an additional 779,095 shares during the quarter. Altimmune makes up 7.9% of Timelo Investment Management Inc.'s holdings, making the stock its largest holding. Timelo Investment Management Inc. owned about 1.51% of Altimmune worth $9,102,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in shares of Altimmune by 65.8% during the 1st quarter. JPMorgan Chase & Co. now owns 307,589 shares of the company's stock worth $1,873,000 after buying an additional 122,021 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of Altimmune by 65.5% during the 1st quarter. MetLife Investment Management LLC now owns 21,184 shares of the company's stock worth $129,000 after buying an additional 8,385 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Altimmune during the 1st quarter worth $1,108,000. Vanguard Group Inc. grew its position in shares of Altimmune by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 1,816,915 shares of the company's stock worth $11,065,000 after buying an additional 83,160 shares in the last quarter. Finally, XTX Topco Ltd grew its position in shares of Altimmune by 33.2% during the 1st quarter. XTX Topco Ltd now owns 19,665 shares of the company's stock worth $120,000 after buying an additional 4,898 shares in the last quarter. Institutional investors own 78.05% of the company's stock.
Altimmune Stock Up 2.1 %
Shares of NASDAQ ALT traded up $0.19 during mid-day trading on Friday, reaching $9.09. 2,933,960 shares of the company were exchanged, compared to its average volume of 4,318,715. The stock has a market cap of $644.44 million, a price-to-earnings ratio of -5.51 and a beta of 0.05. Altimmune, Inc. has a 1 year low of $2.09 and a 1 year high of $14.84. The firm has a 50-day moving average of $9.90 and a 200 day moving average of $7.03.
Analyst Ratings Changes
A number of research firms have recently issued reports on ALT. HC Wainwright dropped their price target on Altimmune from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Monday, April 1st. B. Riley reissued a "buy" rating and set a $20.00 price target on shares of Altimmune in a research report on Thursday, March 28th. Finally, The Goldman Sachs Group began coverage on Altimmune in a research report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price target on the stock.
View Our Latest Stock Analysis on ALT
Altimmune Profile
(
Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Featured Articles
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
